Skip Navigation Home | About CDC | Press Room | Funding | A-Z Index | Centers, Institute & Offices | Training & Employment | Contact Us
CDC Centers for Disease Control and Prevention Home Page
horizontal line  
 

Attention-Deficit / Hyperactivity Disorder (ADHD)
Public Health Concerns in the Treatment of ADHD

The identification and treatment of both children and adults with ADHD is a very politicized and controversial topic. Due to the potential magnitude of the problem, especially among our nation’s youth, and the consequences of large numbers of persons seeking and/or receiving treatment at any given time, long-term outcomes (risks and benefits) of treatment should be monitored to ensure safety and optimal functioning where possible. The most common treatment is the psychopharmacological agent methylphenidate. Due to the lack of research of the long-term efficacy (greater than 24 months and in preschool populations), and safety of such treatment at the population level, a public health perspective should be applied to the treatment of ADHD. The lack of such research, coupled with an increase in length of treatment during the formative growth years, a decrease in the age of initiation into treatment, and growing prevalence estimates, are all causes for concern. As treatment options are considered, it is apparent that more reliance is placed on pharmaceutical remedies than on psychological interventions such as behavior modification, although the latter have been shown to have beneficial effects. This emphasis is apparent even without adequate evidence of long-term academic and functional improvements from pharmacological interventions.

An additional concern in the treatment of ADHD is the issue of comorbidity. Comorbid conditions and health risk behaviors associated with ADHD are often not identified or treated appropriately and those factors result in a significantly higher social cost burden, increased risk for poor educational attainment, and compromised social integration. A public health perspective must be applied to this disorder in a manner that acknowledges and addresses the high risk for comorbidity, secondary conditions, and participation in significant health risk behaviors associated with impulsive and inattentive behavior.

An internal CDC workgroup hosted a one-day meeting with several ADHD experts on this topic to answer specific questions and generate ideas for needed research. The executive summary of this meeting provides detailed questions and answers to related issues.

 

Date: September 20, 2005
Content source: National Center on Birth Defects and Developmental Disabilities

 

horizontal line
Topic Contents
   arrow

What is ADHD
 arrow Symptoms of ADHD
 arrow Peer Relationships
 arrow ADHD & Risk of Injuries
 arrow ADHD & Other Conditions

 arrow Health Perspective
 arrow ADHD Research Agenda
  arrow Resources
  arrow Publications
  arrow Research
horizontal line
blackdots
Quick Links
 arrow

Child Development

 arrow

Tourette Syndrome

  
arrow
Report of the Surgeon General's Conference on Children's Mental Health: A National Action Agenda
  arrow Search Health Topics
  arrow Publications Search
blackdots

Contact Info

Thank you for visiting the CDC-NCBDDD website. Click here to contact the National Center on Birth Defects and Developmental Disabilities

We are not able to answer personal medical questions. Please see your health care provider concerning appropriate care, treatment, or other medical advice.
 

blackdots

Key Resources

Pregnancy-Planning Education Program

Learn the Signs. Act Early.

Learn the Signs - Act Early
 
blackdots

National Center on Birth Defects and Developmental Disabilities

National Center on Birth Defects and Developmental Disabilities
 

 

    Home   |   Policies and Regulations   |   Disclaimer   |   e-Government   |  FOIA   |  Contact Us  
 Safer, Healthier People  FirstGovDHHS Department of Health
and Human Services
Centers for Disease Control and Prevention,1600 Clifton Rd, Atlanta, GA 30333, U.S.A
Public Inquiries: 1-800-CDC-INFO (232-4636); 1-888-232-6348 (TTY), 24 Hours/Every Day - cdcinfo@cdc.gov